Strong NHS Integration Skin Analytics has established a proven track record working closely with NHS organizations since 2020, deploying its AI-powered skin cancer pathways across 25 primary and secondary care facilities. This demonstrates a high level of trust and a solid foundation for expanding into additional health systems seeking advanced cancer diagnostics.

Regulatory and Clinical Validation DERM is uniquely recommended by NICE and holds a Class III CE mark, differentiating it as a trusted and validated AI medical device for skin cancer detection within Europe and the NHS. This regulatory approval facilitates easier adoption by other healthcare providers aiming for high standards of safety and efficacy.

Significant Patient Impact With over 170,000 NHS patients evaluated and more than 15,500 cancers identified, Skin Analytics has demonstrated its ability to improve patient outcomes while reducing hospital appointments by up to 95%. This effectiveness can be leveraged to target health systems looking to optimize cancer pathways and reduce operational costs.

Expansion through Partnerships Recent collaborations with human Bytes in the Nordic countries, European partners like Affidea, and private insurers such as Freedom Health highlight opportunities for international growth and diversification into both public and private healthcare markets, increasing potential sales channels.

Fundraising and Market Credibility With recent funding of $19.9M in Series B and multiple awards recognizing its contribution to cancer outcomes, Skin Analytics is positioned as a credible, innovative player with the capital and industry recognition that can facilitate expansion efforts and new sales initiatives.